Gilead (NASDAQ: GILD) has become the whipping boy du jour for the forthcoming Obamacare-driven cost explosion in government and private health spending. Apparently, everything was going swimmingly until Gilead – right out the blue! – dropped a cure for Hepatitis C on the market and threw everyone’s spending projections into a tizzy.